ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2020 and some content may be unavailable. To unlock all content for 2020, please visit the archives.

Abstract: PUB148

C3 Glomerulonephritis: Diagnostic Challenges and Overlap Syndromes

Session Information

Category: Trainee Case Report

  • 1202 Glomerular Diseases: Immunology and Inflammation

Authors

  • Agarwal, Krishna A., Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
  • Sula Karreci, Esilida, Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
  • Kruger gomes, Larissa, Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
  • Schulman, Ruth, Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
  • Stillman, Isaac Ely, Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
  • Lecker, Stewart H., Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
  • Steinman, Theodore I., Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
  • Denker, Bradley M., Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

Group or Team Name

  • BIDMC
Introduction

C3-glomerulonephritis (C3GN) is a rare complement-mediated GN, with an incidence of 1-3:1,000,000. Spectrum of presentation can range from asymptomatic hematuria and proteinuria to a full blown acute GN with hypertension, hematuria, and renal insufficiency. Serum C3 levels are typically low. Diagnosis is confirmed by renal biopsy. The underlying mechanism appears to be dysregulated alternate complement pathway, triggered by genetic, environmental or a combination of both factors. Medical management addresses blood pressure, proteinuria, and dyslipidemia. Immunosuppression with glucocorticoids, antimetabolites, and anti-complement agents is used alone or in combination. Here we present 2 cases of biopsy-proven C3GN, mimicking infection-associated GN (IAGN) and TTP/HUS.

Case Description

Case 1: A 49-year-old man presented with 4-5 days of fevers, chills, nausea, vomiting and diarrhea. Labs revealed mild thrombocytopenia, proteinuria, microscopic hematuria and a low C3 level. Blood cultures revealed Streptococcus pyogenes. His hospital course was marked by rapidly progressive pancytopenia and hemodialysis-requiring acute renal failure. He received a single dose of eculizumab empirically due to concern for atypical HUS, but platelet counts improved too rapidly to be consistent with eculizumab benefit. Kidney biopsy revealed acute tubular injury with glomerular C3 deposition. EM did not reveal immune deposits. Subsequent renal recovery followed 4 hemodialysis sessions. One-month post-discharge, he had normal renal function and hematologic cell counts.
Case 2: A 74-year-old man with CKD III was admitted with altered mental status, septic shock, and acute kidney injury. Extensive workup did not detect infection or altered autoimmune status. His course was complicated by worsening renal failure, proteinuria, and hematuria. Renal biopsy demonstrated acute tubular injury and glomerular C3 deposition without immune deposits on EM. Eculizumab was deferred due to normal C3 and C4 levels. A steroid pulse was associated with an improvement in creatinine beginning on day 4 and return to baseline kidney function by day 17.

Discussion

Our cases highlight the variable presentation and complexity associated with accurate diagnosis of C3GN, including considerable overlap with IAGN and TTP/HUS.